[Clinical and secretory evaluation of the use of cimetidine in peptic ulcer].
Cimetidine (an H2 receptor blocking agent) was used to treat 35 patients with gastroduodenal peptic ulcer. Endoscopic and secretory controls before and after the treatment showed that pain was reduced in all cases, that complete or partial re-epithelialisation occurred in 33/35, and that there was a significant reduction in basal and post-histamine acid secretion. Alkaline secretion was not significantly altered. Follow-up of the series is regarded as indispensable.
D000293:Adolescent; D000328:Adult; D002927:Cimetidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D005750:Gastric Juice / Q000378:metabolism*; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000503:physiopathology; D011970:Receptors, Histamine H2 / Q000187:drug effects; D012636:Secretory Rate / Q000187:drug effects
D006146:Guanidines; D011970:Receptors, Histamine H2; D002927:Cimetidine
Valutazione clinica e secretoria sull'uso della cimetidina nella patologia peptica.